Exact Mass: 452.25389160000003
Exact Mass Matches: 452.25389160000003
Found 500 metabolites which its exact mass value is equals to given mass value 452.25389160000003,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Repaglinide
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naive to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90\\% of a single orally administered dose is eliminated in feces and 8\\% in urine. C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents
Diphenoxylate
C30H32N2O2 (452.24636519999996)
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07D - Antipropulsives > A07DA - Antipropulsives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
Bisbenzimide
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D020011 - Protective Agents > D011837 - Radiation-Protective Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes D011838 - Radiation-Sensitizing Agents Bisbenzimide. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=23491-52-3 (retrieved 2024-08-14) (CAS RN: 23491-52-3). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Rhodojaponin I
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits. (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is a constituent of Physalis peruviana (Cape gooseberry) Constituent of Physalis peruviana (Cape gooseberry). (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits.
Tafluprost
C25H34F2O5 (452.23741780000006)
Tafluprost is only found in individuals that have used or taken this drug. It is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Tafluprost was approved for use in the U.S. on February 10, 2012.Tafluprost is a prostaglandin F2a analogue. Specifically, Tafluprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78568 - Prostaglandin Analogue
PA(10:0/8:0)
C21H41O8P (452.25389160000003)
PA(10:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/8:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/10:0)
C21H41O8P (452.25389160000003)
PA(8:0/10:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/10:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of capric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
Delapril
Tribendimidine
Tribendimidine is an orally active, broad-spectrum anthelmintic agent, with particularly high activity against A. lumbricoides and N. americanus. Tribendimidine is also an L-type nicotinic acetylcholine receptor (nAChR) agonist[1][2][3].
DG(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
DG(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0/0:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
DG(2:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/2:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
DG(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0/0:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
DG(2:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/2:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
DG(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0/0:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
DG(2:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/2:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
7-O-Demethylisocephaeline
A pyridoisoquinoline consisting of (1beta)-emetan substituted by hydroxy groups at positions 6 and 7 and methoxy groups at positions 10 and 11. It is isolated from Psychotria klugii and exhibits antileishmanial activity.
(E)-5-hydroxy-N-[3-[5-[3-[[(E)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide
[(1S,2R,4aR,8aR)-1-acetyloxy-1,4a-dimethyl-6-oxo-7-propan-2-ylidene-2,3,4,5,8,8a-hexahydronaphthalen-2-yl] 3-acetyloxy-2-hydroxy-2-methylbutanoate
2-Picenecarboxylic acid
methyl-13S-hydroxy-14R,15-diacetoxy-1(10)-ent-halimen-18-oate
(20R,22R)-21,24-epoxy-5beta-hydroxy-1-oxowitha-2,9(11),25(27)-trienolide|withametelinol-A
10-hidroxy 4,17-dihydro 17 beta-tchibangensine
C29H32N4O (452.25759819999996)
Toxin III (Helminthosporium carbonum)
C21H32N4O7 (452.22708819999997)
2??,5??,9??-Trihydroxy-10??,13??-diacetoxy-4??,20-epoxytaxa-11-ene
14,15-Di-Ac,17-Me ester-13,14,15-Trihydroxy-7-labden-17-oic acid
(15R)-scutecyprol A|15beta-scutecyprol A|15R-scutecyprol A|clerodin hemiacetal
(2beta,3beta,5alpha,6alpha)-2,3-bis(acetyloxy)-8,13-epoxy-6,9-dihydroxylabd-14-en-11-one|(3R,4aR,6S,6aS,8R,9S,10aS,10bS)-8,9-bis(acetyloxy)-3-ethenyldodecahydro-6,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one|excolabdone A
7alpha,12alpha,14beta,15beta-tetrahydroxy-3beta,19-diacetoxy-ent-kaur-16-ene|pharicinin D
3beta,6alpha,11beta,15beta-tetrahydroxy-1alpha,7beta-diacetoxy-ent-kaur-16-ene|nervonin F
1alpha,3beta,6alpha,15beta-tetrahydroxy-7beta,11beta-diacetoxy-ent-kaur-16-ene|nervonin I
(1alpha,5alpha,6beta,7beta)-1,6-bis(acetyloxy)-8,13-epoxy-7,9-dihydroxylabd-14-en-11-one|(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10-bis(acetyloxy)-3-ethenyldodecahydro-5,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho[2,1-b]pyran-1-one|excolabdone B
antidesmanin E|antidesmanin F|erythro-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol|threo-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol
(20R,22R)-17beta-hydroxy-1,12-dioxowitha-2,5,24-trien-26,22-olide|jaborosalactone 44
9alpha,10beta-diacetoxy-2alpha,5alpha,14beta-trihydroxy-4,20-epoxy,11-taxene
3-epi-14,15-dihydrocaryoptinol|3beta-hydroxy-14,15-dihydroclerodin|ajubractin E
7beta,11alpha-diacetoxy-8,13-epoxy-6beta,9alpha-dihydroxylabd-14-ene-1-one|coleoforskolin
(3R,4S,5R,6R,2R,3S)-3-O-(2,3-diacetoxy-2-methylbutyryl)cuauhtemone
1-[11-(ferulyloxy)undecanoyl]glycerol|2,3-dihydroxypropyl 11-{[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}undecanoate
24,25,26,27-tetra-norapotirucalla-(apoeupha)-6alpha-acetoxy-7alpha-hydroxy-1,14,20,22-tetraen-21,23-epoxy-3-one|6alpha-O-acetyl-7-deacetylnimocinol
18-methylmalonyl-7alpha-hydroxy-methyltrineracetal
(22R)-4beta,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide|(4S,20S,22R)-4,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,5,16,22-tetraenolide
3,22beta-dihydroxy-24,29-dinor-1(10),3,5-friedelatriene-2,7,21-trione
6alpha,8alpha,23,14,15-erythro-pentahydroxy-labd-13(21),17-dien-16,19-olide|6alpha,8alpha,23,14,15-threo-pentahydroxy-labd-13(21),17-dien-16,19-olide
(22R,Z)-16beta,27-dihydroxy-1-oxo-witha-2,5,17(20),24-tetraenolide
3,7,9-trihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,4,6,24-tetraenolide|14alpha,20alphaF-dihydroxy-1-oxo-22R-witha-2,4,6,24-tetraenolide
6beta,7beta,11beta,14beta,15beta-pentahydroxy-20-isoamoxy-7alpha,20-epoxy-ent-kaur-16-ene|hebeirubescensin F
16-en-27-deoxywithaferin A|27-deoxy-Delta(16)-withaferin A|5beta,6beta-epoxy-4beta-hydroxy-1-oxo-witha-2,16,24-trienolide
1-(18-hydroxyoleoyl)-sn-glycrol 3-phosphate
C21H41O8P (452.25389160000003)
Repaglinide
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents CONFIDENCE standard compound; INTERNAL_ID 2189 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3349
Diphenoxylate
C30H32N2O2 (452.24636519999996)
A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07D - Antipropulsives > A07DA - Antipropulsives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
C28H36O5_2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,8,12b,13,14,14a,14b-tetradecahydro-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-, (2R,4aS,6aS,12bR,14aS,14bR)
C24H36O8_Butanoic acid, 3-(acetyloxy)-2-hydroxy-2-methyl-, (1S,2R,4aR,8aR)-1-(acetyloxy)decahydro-1,4a-dimethyl-7-(1-methylethylidene)-6-oxo-2-naphthalenyl ester
(2R,4aS,6aR,6aS,14aS,14bR)-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
[(1S,2R,4aR,8aR)-1-acetyloxy-1,4a-dimethyl-6-oxo-7-propan-2-ylidene-2,3,4,5,8,8a-hexahydronaphthalen-2-yl] 3-acetyloxy-2-hydroxy-2-methylbutanoate_major
Ala His Ile Ile
Ala His Ile Leu
Ala His Leu Ile
Ala His Leu Leu
Ala Ile His Ile
Ala Ile His Leu
Ala Ile Ile His
Ala Ile Leu His
Ala Ile Ser Tyr
C21H32N4O7 (452.22708819999997)
Ala Ile Tyr Ser
C21H32N4O7 (452.22708819999997)
Ala Leu His Ile
Ala Leu His Leu
Ala Leu Ile His
Ala Leu Leu His
Ala Leu Ser Tyr
C21H32N4O7 (452.22708819999997)
Ala Leu Tyr Ser
C21H32N4O7 (452.22708819999997)
Ala Ser Ile Tyr
C21H32N4O7 (452.22708819999997)
Ala Ser Leu Tyr
C21H32N4O7 (452.22708819999997)
Ala Ser Tyr Ile
C21H32N4O7 (452.22708819999997)
Ala Ser Tyr Leu
C21H32N4O7 (452.22708819999997)
Ala Thr Val Tyr
C21H32N4O7 (452.22708819999997)
Ala Thr Tyr Val
C21H32N4O7 (452.22708819999997)
Ala Val Thr Tyr
C21H32N4O7 (452.22708819999997)
Ala Val Tyr Thr
C21H32N4O7 (452.22708819999997)
Ala Tyr Ile Ser
C21H32N4O7 (452.22708819999997)
Ala Tyr Leu Ser
C21H32N4O7 (452.22708819999997)
Ala Tyr Ser Ile
C21H32N4O7 (452.22708819999997)
Ala Tyr Ser Leu
C21H32N4O7 (452.22708819999997)
Ala Tyr Thr Val
C21H32N4O7 (452.22708819999997)
Ala Tyr Val Thr
C21H32N4O7 (452.22708819999997)
Phe Ile Ser Ser
C21H32N4O7 (452.22708819999997)
Phe Leu Ser Ser
C21H32N4O7 (452.22708819999997)
Phe Ser Ile Ser
C21H32N4O7 (452.22708819999997)
Phe Ser Leu Ser
C21H32N4O7 (452.22708819999997)
Phe Ser Ser Ile
C21H32N4O7 (452.22708819999997)
Phe Ser Ser Leu
C21H32N4O7 (452.22708819999997)
Phe Ser Thr Val
C21H32N4O7 (452.22708819999997)
Phe Ser Val Thr
C21H32N4O7 (452.22708819999997)
Phe Thr Ser Val
C21H32N4O7 (452.22708819999997)
Phe Thr Val Ser
C21H32N4O7 (452.22708819999997)
Phe Val Ser Thr
C21H32N4O7 (452.22708819999997)
Phe Val Thr Ser
C21H32N4O7 (452.22708819999997)
b-D-Glucopyranosiduronic acid, (3a,5b)-17-oxoestran-3-yl
b-D-Glucopyranosiduronic acid, (3b,5a)-17-oxoestran-3-yl
b-D-Glucopyranosiduronic acid, (3b,5b)-17-oxoestran-3-yl
Gly Ile Thr Tyr
C21H32N4O7 (452.22708819999997)
Gly Ile Tyr Thr
C21H32N4O7 (452.22708819999997)
Gly Leu Thr Tyr
C21H32N4O7 (452.22708819999997)
Gly Leu Tyr Thr
C21H32N4O7 (452.22708819999997)
Gly Thr Ile Tyr
C21H32N4O7 (452.22708819999997)
Gly Thr Leu Tyr
C21H32N4O7 (452.22708819999997)
Gly Thr Tyr Ile
C21H32N4O7 (452.22708819999997)
Gly Thr Tyr Leu
C21H32N4O7 (452.22708819999997)
Gly Tyr Ile Thr
C21H32N4O7 (452.22708819999997)
Gly Tyr Leu Thr
C21H32N4O7 (452.22708819999997)
Gly Tyr Thr Ile
C21H32N4O7 (452.22708819999997)
Gly Tyr Thr Leu
C21H32N4O7 (452.22708819999997)
His Ala Ile Ile
His Ala Ile Leu
His Ala Leu Ile
His Ala Leu Leu
His Ile Ala Ile
His Ile Ala Leu
His Ile Ile Ala
His Ile Leu Ala
His Ile Pro Ser
His Ile Ser Pro
His Leu Ala Ile
His Leu Ala Leu
His Leu Ile Ala
His Leu Leu Ala
His Leu Pro Ser
His Leu Ser Pro
His Pro Ile Ser
His Pro Leu Ser
His Pro Ser Ile
His Pro Ser Leu
His Pro Thr Val
His Pro Val Thr
His Ser Ile Pro
His Ser Leu Pro
His Ser Pro Ile
His Ser Pro Leu
His Thr Pro Val
His Thr Val Pro
His Val Pro Thr
His Val Thr Pro
His Val Val Val
Ile Ala His Ile
Ile Ala His Leu
Ile Ala Ile His
Ile Ala Leu His
Ile Ala Ser Tyr
C21H32N4O7 (452.22708819999997)
Ile Ala Tyr Ser
C21H32N4O7 (452.22708819999997)
Ile Phe Ser Ser
C21H32N4O7 (452.22708819999997)
Ile Gly Thr Tyr
C21H32N4O7 (452.22708819999997)
Ile Gly Tyr Thr
C21H32N4O7 (452.22708819999997)
Ile His Ala Ile
Ile His Ala Leu
Ile His Ile Ala
Ile His Leu Ala
Ile His Pro Ser
Ile His Ser Pro
Ile Ile Ala His
Ile Ile His Ala
Ile Leu Ala His
Ile Leu His Ala
Ile Pro His Ser
Ile Pro Ser His
Ile Ser Ala Tyr
C21H32N4O7 (452.22708819999997)
Ile Ser Phe Ser
C21H32N4O7 (452.22708819999997)
Ile Ser His Pro
Ile Ser Pro His
Ile Ser Ser Phe
C21H32N4O7 (452.22708819999997)
Ile Ser Tyr Ala
C21H32N4O7 (452.22708819999997)
Ile Thr Gly Tyr
C21H32N4O7 (452.22708819999997)
Ile Thr Tyr Gly
C21H32N4O7 (452.22708819999997)
Ile Tyr Ala Ser
C21H32N4O7 (452.22708819999997)
Ile Tyr Gly Thr
C21H32N4O7 (452.22708819999997)
Ile Tyr Ser Ala
C21H32N4O7 (452.22708819999997)
Ile Tyr Thr Gly
C21H32N4O7 (452.22708819999997)
Leu Ala His Ile
Leu Ala His Leu
Leu Ala Ile His
Leu Ala Leu His
Leu Ala Ser Tyr
C21H32N4O7 (452.22708819999997)
Leu Ala Tyr Ser
C21H32N4O7 (452.22708819999997)
Leu Phe Ser Ser
C21H32N4O7 (452.22708819999997)
Leu Gly Thr Tyr
C21H32N4O7 (452.22708819999997)
Leu Gly Tyr Thr
C21H32N4O7 (452.22708819999997)
Leu His Ala Ile
Leu His Ala Leu
Leu His Ile Ala
Leu His Leu Ala
Leu His Pro Ser
Leu His Ser Pro
Leu Ile Ala His
Leu Ile His Ala
Leu Leu Ala His
Leu Leu His Ala
Leu Pro His Ser
Leu Pro Ser His
Leu Ser Ala Tyr
C21H32N4O7 (452.22708819999997)
Leu Ser Phe Ser
C21H32N4O7 (452.22708819999997)
Leu Ser His Pro
Leu Ser Pro His
Leu Ser Ser Phe
C21H32N4O7 (452.22708819999997)
Leu Ser Tyr Ala
C21H32N4O7 (452.22708819999997)
Leu Thr Gly Tyr
C21H32N4O7 (452.22708819999997)
Leu Thr Tyr Gly
C21H32N4O7 (452.22708819999997)
Leu Tyr Ala Ser
C21H32N4O7 (452.22708819999997)
Leu Tyr Gly Thr
C21H32N4O7 (452.22708819999997)
Leu Tyr Ser Ala
C21H32N4O7 (452.22708819999997)
Leu Tyr Thr Gly
C21H32N4O7 (452.22708819999997)
Pro His Ile Ser
Pro His Leu Ser
Pro His Ser Ile
Pro His Ser Leu
Pro His Thr Val
Pro His Val Thr
Pro Ile His Ser
Pro Ile Ser His
Pro Leu His Ser
Pro Leu Ser His
Pro Ser His Ile
Pro Ser His Leu
Pro Ser Ile His
Pro Ser Leu His
Pro Thr His Val
Pro Thr Val His
Pro Val His Thr
Pro Val Thr His
Ser Ala Ile Tyr
C21H32N4O7 (452.22708819999997)
Ser Ala Leu Tyr
C21H32N4O7 (452.22708819999997)
Ser Ala Tyr Ile
C21H32N4O7 (452.22708819999997)
Ser Ala Tyr Leu
C21H32N4O7 (452.22708819999997)
Ser Phe Ile Ser
C21H32N4O7 (452.22708819999997)
Ser Phe Leu Ser
C21H32N4O7 (452.22708819999997)
Ser Phe Ser Ile
C21H32N4O7 (452.22708819999997)
Ser Phe Ser Leu
C21H32N4O7 (452.22708819999997)
Ser Phe Thr Val
C21H32N4O7 (452.22708819999997)
Ser Phe Val Thr
C21H32N4O7 (452.22708819999997)
Ser His Ile Pro
Ser His Leu Pro
Ser His Pro Ile
Ser His Pro Leu
Ser Ile Ala Tyr
C21H32N4O7 (452.22708819999997)
Ser Ile Phe Ser
C21H32N4O7 (452.22708819999997)
Ser Ile His Pro
Ser Ile Pro His
Ser Ile Ser Phe
C21H32N4O7 (452.22708819999997)
Ser Ile Tyr Ala
C21H32N4O7 (452.22708819999997)
Ser Leu Ala Tyr
C21H32N4O7 (452.22708819999997)
Ser Leu Phe Ser
C21H32N4O7 (452.22708819999997)
Ser Leu His Pro
Ser Leu Pro His
Ser Leu Ser Phe
C21H32N4O7 (452.22708819999997)
Ser Leu Tyr Ala
C21H32N4O7 (452.22708819999997)
Ser Pro His Ile
Ser Pro His Leu
Ser Pro Ile His
Ser Pro Leu His
Ser Ser Phe Ile
C21H32N4O7 (452.22708819999997)
Ser Ser Phe Leu
C21H32N4O7 (452.22708819999997)
Ser Ser Ile Phe
C21H32N4O7 (452.22708819999997)
Ser Ser Leu Phe
C21H32N4O7 (452.22708819999997)
Ser Thr Phe Val
C21H32N4O7 (452.22708819999997)
Ser Thr Val Phe
C21H32N4O7 (452.22708819999997)
Ser Val Phe Thr
C21H32N4O7 (452.22708819999997)
Ser Val Thr Phe
C21H32N4O7 (452.22708819999997)
Ser Tyr Ala Ile
C21H32N4O7 (452.22708819999997)
Ser Tyr Ala Leu
C21H32N4O7 (452.22708819999997)
Ser Tyr Ile Ala
C21H32N4O7 (452.22708819999997)
Ser Tyr Leu Ala
C21H32N4O7 (452.22708819999997)
Thr Ala Val Tyr
C21H32N4O7 (452.22708819999997)
Thr Ala Tyr Val
C21H32N4O7 (452.22708819999997)
Thr Phe Ser Val
C21H32N4O7 (452.22708819999997)
Thr Phe Val Ser
C21H32N4O7 (452.22708819999997)
Thr Gly Ile Tyr
C21H32N4O7 (452.22708819999997)
Thr Gly Leu Tyr
C21H32N4O7 (452.22708819999997)
Thr Gly Tyr Ile
C21H32N4O7 (452.22708819999997)
Thr Gly Tyr Leu
C21H32N4O7 (452.22708819999997)
Thr His Pro Val
Thr His Val Pro
Thr Ile Gly Tyr
C21H32N4O7 (452.22708819999997)
Thr Ile Tyr Gly
C21H32N4O7 (452.22708819999997)
Thr Leu Gly Tyr
C21H32N4O7 (452.22708819999997)
Thr Leu Tyr Gly
C21H32N4O7 (452.22708819999997)
Thr Pro His Val
Thr Pro Val His
Thr Ser Phe Val
C21H32N4O7 (452.22708819999997)
Thr Ser Val Phe
C21H32N4O7 (452.22708819999997)
Thr Val Ala Tyr
C21H32N4O7 (452.22708819999997)
Thr Val Phe Ser
C21H32N4O7 (452.22708819999997)
Thr Val His Pro
Thr Val Pro His
Thr Val Ser Phe
C21H32N4O7 (452.22708819999997)
Thr Val Tyr Ala
C21H32N4O7 (452.22708819999997)
Thr Tyr Ala Val
C21H32N4O7 (452.22708819999997)
Thr Tyr Gly Ile
C21H32N4O7 (452.22708819999997)
Thr Tyr Gly Leu
C21H32N4O7 (452.22708819999997)
Val His Pro Thr
Val His Thr Pro
Val His Val Val
Val Pro His Thr
Val Pro Thr His
Val Thr His Pro
Val Thr Pro His
Val Val His Val
Val Val Val His
Tafluprost
C25H34F2O5 (452.23741780000006)
S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EE - Prostaglandin analogues C78568 - Prostaglandin Analogue
octadecanoic acid-1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl ester
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
Delapril
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
tert-Butyl-{3-[2-(diphenyl-phosphinoyl)-ethylidene]-4-methylene-cyclohexyloxy}-dimethyl-silane
1-Propanol, 2-methoxy-3-[(9Z)-9-octadecenyloxy]-, dihydrogen phosphorothioate, (2R)
C22H45O5PS (452.27251700000005)
1-hexadecyl-3-methylimidazolium hexafluorophosphate
GDC-0349
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes. GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.
Etripamil
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Bofutrelvir
COVID info from PDB, Protein Data Bank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C281 - Antiviral Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Paraminabeolide F
A withanolide that is 18,22:23,26-diepoxyergosta-1,4-diene substituted by oxo groups at positions 3, 18 and 26. It has been isolated from a Formosan soft coral Paraminabea acronocephala.
Butropium
C28H38NO4+ (452.28006880000004)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
2-Ethoxy-4-[2-[[3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
EleutherazineB
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines
N-hexadecanoyl-sn-glycero-3-phosphoethanolamine(1-)
C21H43NO7P- (452.27769980000005)
[(2R)-2-hydroxy-3-phosphonooxypropyl] (Z)-18-hydroxyoctadec-9-enoate
C21H41O8P (452.25389160000003)
Ala-Leu-Leu-His
A tetrapeptide composed of L-alanine, two L-leucine units, and an L-histidine joined in sequence.
epiandrosterone 3-beta-D-glucoside
A sterol 3-beta-D-glucoside that has epiandrosterone as the sterol component.
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(2-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(3-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(4-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
[(1S,3S,4R,6R,8S,9S,10R,11R,14R,15R,17R)-17-acetyloxy-4,10,15-trihydroxy-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.01,11.04,9.06,8]heptadecan-3-yl] acetate
[(E)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1S,6R)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-enyl] hydrogen sulfate
C25H40O5S (452.25963100000007)
(2S,3S,3aR,9bR)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
(2R,3R,3aS,9bS)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
(2S,3S,3aR,9bR)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester
2-[[(2R)-2-acetyloxy-3-undec-10-enoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C21H43NO7P+ (452.27769980000005)
(1-Acetyloxy-3-phosphonooxypropan-2-yl) hexadecanoate
C21H41O8P (452.25389160000003)
(2-Nonanoyloxy-3-phosphonooxypropyl) nonanoate
C21H41O8P (452.25389160000003)
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) pentadecanoate
C21H41O8P (452.25389160000003)
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) dodecanoate
C21H41O8P (452.25389160000003)
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) tetradecanoate
C21H41O8P (452.25389160000003)
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) undecanoate
C21H41O8P (452.25389160000003)
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) tridecanoate
C21H41O8P (452.25389160000003)
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) decanoate
C21H41O8P (452.25389160000003)
2-[hydroxy-[2-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
C21H43NO7P+ (452.27769980000005)
Bisbenzimide
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D020011 - Protective Agents > D011837 - Radiation-Protective Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes D011838 - Radiation-Sensitizing Agents
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] decanoate
C21H41O8P (452.25389160000003)
lysophosphatidylethanolamine zwitterion 16:0
C21H43NO7P (452.27769980000005)
A lysophosphatidylethanolamine zwitterion in which the remaining acyl group (position not specified) contains 16 carbons and 0 double bonds.
phosphatidic acid 18:0
C21H41O8P (452.25389160000003)
A phosphatidic acid in which the two acyl groups contain a total of 18 carbons and no double bonds.
GSK3326595
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].
2-ethoxy-4-({[(1s)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]-c-hydroxycarbonimidoyl}methyl)benzoic acid
(1r,2r,8s,10r,11r,15r,16s)-15-(furan-3-yl)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-10-yl acetate
(1s,2s,4s,5s,8r,9s,10z,12r)-12-hydroxy-8-isopropyl-1,5,11-trimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-6,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate
(1r,5r,8r)-8-[(1r,3as,3bs,5as,9ar,11as)-5a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,6h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1s,2r,4r,6r,7s,10r,11r,16r,18r)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
(1r,2r,3r,4s,6s,9s,10s,11s,13s,14s,16s)-6-(acetyloxy)-2,16-dihydroxy-13-(hydroxymethyl)-5,5,9-trimethyl-12-oxapentacyclo[11.2.1.1¹¹,¹⁴.0¹,¹⁰.0⁴,⁹]heptadecan-3-yl acetate
(1s,2r,4s,8r,9r,10s,14s,15r)-9-(acetyloxy)-2-hydroxy-1,10,14-trimethyl-5-methylidene-6-oxo-7,18-dioxatricyclo[13.2.1.0⁴,⁸]octadecan-14-yl acetate
8-(acetyloxy)-3,6,11,15-tetrahydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-2-yl acetate
6-(1-{3a-hydroxy-9a,11a-dimethyl-9-oxo-3h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
(2-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
1-(furan-2-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
(2r,4as,6as,12br,14as,14br)-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
(1s,2s,6s,7s,9r,13r,14s,15r,16s,17r)-11,14-dihydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate
(1r,3as,3br,9ar,9bs,11as)-1-[(1r)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-1-hydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,9bh,10h-cyclopenta[a]phenanthrene-9,11-dione
1-({3-ethyl-10-hydroxy-9-methoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}methyl)-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol
6-(1-{6-hydroxy-9a,11a-dimethyl-9-oxo-3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
20-methyl-7,17,21,31-tetraazaoctacyclo[19.10.1.0³,¹⁹.0⁵,¹⁷.0⁶,¹⁴.0⁸,¹³.0²²,²⁷.0²⁸,³²]dotriaconta-6(14),8,10,12,18,22,24,26-octaen-11-ol
C29H32N4O (452.25759819999996)
11,14-dihydroxy-4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate
(1s,2r,7s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1s,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
5-[12-(chloromethylidene)-4-hydroxy-3,6,9-trimethyltetracyclo[6.6.1.0²,⁶.0¹¹,¹⁵]pentadeca-7,11(15)-dien-3-yl]-2-methylpentane-1,2,3,4-tetrol
C25H37ClO5 (452.23293820000004)